Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma
Hiroyuki Kashiwagi, Jonathan E. McDunn, Peter O. Simon, Peter S. Goedegebuure, Suwanna Vangveravong, Katherine Chang, Richard S. Hotchkiss, Robert H. Mach, William G. Hawkins
Dive into the research topics of 'Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma'. Together they form a unique fingerprint.